LEXICON PHARMACEUTICALS INC. - COMMON STOCK

Lexicon Welcomes New ESC Heart Failure Treatment Guidelines Establishing SGLT Inhibitors as Standard of Care

30 Aug 2021 07:00:00 By Nasdaq GlobeNewswire

Lexicon’s Sotagliflozin Demonstrates Additional Compelling Benefits in Reducing Cardiovascular Endpoints: Results from Soloist and Scored Trials

23 Aug 2021 06:09:19 By Nasdaq GlobeNewswire

Craig Granowitz, M.D., Ph.D. Joins Lexicon as Senior Vice President and Chief Medical Officer

30 Jul 2021 07:01:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical Update

30 Jul 2021 07:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Host Second Quarter 2021 Financial Results Conference Call and Webcast on July 30, 2021

28 Jul 2021 17:40:44 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Announces Symposium at the American Diabetes Association 81st Scientific Sessions

25 Jun 2021 08:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in the 2021 Jefferies Virtual Healthcare Conference

26 May 2021 16:15:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Announces Two Presentations at the American College of Cardiology’s 70th Annual Scientific Session

13 May 2021 16:15:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical Update

06 May 2021 16:05:01 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Host First Quarter 2021 Financial Results Conference Call and Webcast on May 6, 2021

29 Apr 2021 16:13:55 By Nasdaq GlobeNewswire